1. A method of treating an autoimmune disorder in a human subject, comprising administering to the subject an antibody or antigen binding fragment thereof that specifically binds to human interferon alfa, where, after administration, one or more pharmacokinetic characteristics selected from immune clearance are obtained (CL, CL, CL / F or CL / F) from about 99 to about 432 ml / day, an apparent volume of distribution (V or V / F) from about 3 to about 17 L and a half-life from serum from about 14 to about 48 days； and where the autoimmune disorder is systemic lupus erythematosus, scleroderma, or myositis. 2. The method of claim 1, wherein the antibody or antigen binding fragment thereof binds to an epitope on human interferon alpha recognized by an antibody containing a variable region of the heavy chain containing the amino acid sequence of SEQ ID NO: 19 and a variable region of the light chain containing the amino acid sequence of SEQ ID NO : 22.3. The method of claim 1 or 2, wherein the antibody or antigen binding fragment thereof comprises (a) a heavy chain variable region CDR1 comprising SEQ ID NO: 1； (b) CDR2 of the variable region of the heavy chain containing SEQ ID NO: 4； (c) CDR3 of the variable region of the heavy chain containing SEQ ID NO: 7； (d) CDR1 of the variable region of the light chain containing SEQ ID NO: 10； (e) CDR2 of the variable region of the light chain containing SEQ ID NO: 13； and (f) CDR3 of the variable region of the light chain containing SEQ ID NO: 16.4. The method of claim 1, wherein the antibody or antigen binding fragment thereof comprises (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 19, SEQ ID NO: 34, SEQ1. Способ лечения аутоиммунного нарушения у субъекта, являющегося человеком, включающий введение субъекту антитела или его антигенсвязующего фрагмента, которое специфически связываются с человеческим интерфероном альфа, где после введения получают одну или более фармакокинетических характери
